Imugene Ltd · ASX:IMU

Imugene — Shareholder Meeting (November 2019)

10 slides from Imugene's shareholder meeting presentation, Nov 8, 2019

  1. Slide 1: Imugene AGM, 8th November 2019

    For personal use only Imugene AGM 8th November 2019

  2. Slide 2: Experienced management team with significant clinical development expertise

    Experienced management team which have significant clinical development expertise Dr Mark Marino Dr Nick Ede For personal use only SAN DIEGO, USA MELBOURNE, AU Chief Medical Officer Chief Technology Officer • 28+ years of experience in drug • 25+ years peptide vaccine and development drug developmen

  3. Slide 3: 2018 - 2019 Year in Review

    2018 - 2019 Year in Review  Successful integration of Ohio Sate University B Cell immunotherapies For personal use only  Commencement of PD-1 manufacturing  Successful Pre-IND FDA meeting for guidance for PD1-Vaxx Clinical Development Plan  Met endpoints in Phase 1B HER-Vaxx gastric study  Firs

  4. Slide 4: HER-Vaxx Publications in Major Cancer Conferences

    HER-Vaxx PUBLICATIONS in MAJOR CANCER CONFERENCES AACR ESMO-GI ASCO ESMO For personal use only AACR 2019 ESMO-GI 2019 ASCO 2019 ESMO-2019 A Phase Ib open label multicenter study A Phase 1B study of IMU-131 HER2/NEU A Phase 1b study of IMU-131 HER2/NEU Comprehensive results of a Phase Ib study with a

  5. Slide 5: PD1-Vaxx Publications Major Cancer Conferences

    PD1-Vaxx PUBLICATIONS MAJOR CANCER CONFERENCES AACR ESMO For personal use only AACR 2019 ESMO-2019 Development of a novel PD-1 vaccine Antitumor activity and safety of a novel PD- and in combination with two Chimeric 1 vaccine (PD1-Vaxx) alone and in HER-2 peptide vaccine provides combination with t

  6. Slide 6: Proposed Vaxinia CF33 Oncolytic Virus (OV) Acquisition

    Proposed Vaxinia CF33 Oncolytic Virus (OV) Acquisition  OVs are a promising area of immuno-oncology and of focused interest to Big For personal use only Pharma  Vaxinia offers IMU the opportunity of entering the OV field at a relatively advanced stage of development  Two clinical trials are forec

  7. Slide 7: CF33 Management Team

    CF33 MANAGEMENT TEAM Paul Hopper For personal use only Executive Chairman Leslie Chong MD & CEO Dr Len Post Mark Grose Dr Seymour Fein Dr Evan Siegal Dr Mike White Dr Nick Ede Senior Scientific Clinical Trials Medical Monitor IND Lead on Vaxinia Biostatistician Advisor Manager IND Submission Former

  8. Slide 8: Multiple Near & Medium Term Value Inflection Points

    MULTIPLE NEAR & MEDIUM TERM VALUE INFLECTION POINTS For personal use only Next 12 months 8

  9. Slide 9: Financial Summary

    For personal use only Financial Summary Public Market Overview Share Price Performance (last 6 months) Share Price 1 A$0.023 Market Capitalisation 2 A$83.1M IMU announced EGM and IMU announced proposed Clinical Development of Cash equivalents (30 Sep 19 acquistion of CF33 CF33 A$17.8M + R&D rebate)

  10. Slide 10: Leslie Chong, Managing Director & CEO

    For personal use only Leslie Chong Managing Director & CEO leslie.chong@imugene.com +61 458 040 433

Imugene — Shareholder Meeting (November 2019) on 6ix